Overskuddet stiger 40% hos EuroNav

Overskuddet stiger 40% hos EuroNav

Som forventet sejlede EuroNav endnu et stærkt kvartal hjem. Faktisk det bedste første kvartal i 8 år. Det var egentligt ventet, men at overskuddet for kvartalet skulle stige fra $80 millioner til $113 millioner er nok en overraskelse.Den ekstra stærke stigning ovenpå en omsætning der steg 5% fra Q1 2015 er dog positivt påvirket af et salg af et skib …

Read more.

---

Biotek update - premarket

Som vi skrev om igår inden FDA høringen, så ville Sarepta få yderst svært ved at vende høringen til noget positivt, på trods af at man lagde massivt pres på med følelsesladede indlæg fra patienter og politikere. Det var faktisk lidt af en historisk høring igår af flere grunde og videnskabsfolkene/lægerne var tydeligt påvirket af det massive pres. Men det kunne …

Read more.

---
Cabozantinib godkendt - Exelixis stiger 5% (opdateret 26. april)

Cabozantinib godkendt - Exelixis stiger 5% (opdateret 26. april)

Som vi tidligere skrev var der sandsynlighed for at Exelixis fik godkendt Cabozantinib inden midt maj. Du kan læse artiklen her.  Idag skete det så, hvilket er en kæmpe milepæl for selskabet der selv har et 80 mand stort amerikansk salgshold klar. Det sker lige inden deres kvartalsmeddelelse 5. maj. Her efter luk er selskabets aktier oppe i 4,66-4,85 niveauet, men der kan ligge meget …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.